- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
Patent holdings for IPC class A61K 31/138
Total number of patents in this class: 2029
10-year publication summary
|
174
|
156
|
147
|
165
|
164
|
230
|
177
|
162
|
140
|
99
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Antecip Bioventures II LLC | 338 |
57 |
| Apnimed, Inc. (Delaware) | 51 |
27 |
| Novartis AG | 10727 |
21 |
| Genentech, Inc. | 3979 |
21 |
| The Regents of the University of California | 20015 |
20 |
| Duke University | 3078 |
18 |
| Pharnext | 91 |
18 |
| Ohemo Life Sciences Inc | 23 |
18 |
| Jina Pharmaceuticals, Inc. | 34 |
17 |
| Saniona A/S | 48 |
16 |
| Atossa Therapeutics, Inc. | 57 |
16 |
| Emory University | 1625 |
14 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3174 |
14 |
| The Board of Trustees of the University of Illinois | 2704 |
13 |
| Actimed Therapeutics Limited | 26 |
13 |
| Curasen Therapeutics, Inc. | 47 |
13 |
| Nalpropion Pharmaceuticals LLC | 73 |
11 |
| The Procter & Gamble Company | 22031 |
10 |
| Centre National de La Recherche Scientifique | 10476 |
10 |
| Repros Therapeutics Inc. | 36 |
10 |
| Other owners | 1672 |